According to a recent LinkedIn post from Springbok Analytics, Chief Science Officer and Co-Founder Silvia Blemker, Ph.D., is expected to speak at the Hereditary Neuropathy Foundation CMT Summit & Health & Wellness Retreat 2026 in Maryland. The post indicates she will present on translating MRI into quantitative muscle health insights for individuals with Charcot-Marie-Tooth disease.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post also notes that team member Brian Reichert plans to attend to connect with clinicians, researchers, and patient advocates and to assess needs within the CMT community. For investors, this visibility at a specialized neuromuscular disease conference suggests ongoing efforts to validate Springbok’s advanced muscle analytics in rare-disease care settings, which could support future adoption, partnerships, and research collaborations.